Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 17/20 | 1.00 |
| ▸ | ABL1 | P00519 | 13/20 | 1.00 |
| ▸ | ABL2 | P42684 | 13/20 | 1.00 |
| ▸ | EGFR | P00533 | 3/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.58 |
| ▸ | FLT1 | P17948 | 1/20 | 0.58 |
| ▸ | FLT4 | P35916 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30453000 | 1.00 | SRC (1.00) | SRCABL1ABL2EGFRFGFR1 | |
| SCHEMBL3152705 | 0.96 | SRC (0.92) | SRCABL1ABL2EGFRFGFR1 | |
| SCHEMBL28565311 | 0.93 | SRC (0.88) | SRCABL1ABL2EGFRKDR | |
| SCHEMBL6187802 | 0.92 | SRC (0.85) | SRCABL1ABL2EGFRFYN | |
| SCHEMBL1659719 | 0.90 | SRC (1.00) | SRCABL1ABL2 | |
| SCHEMBL30452732 | 0.90 | SRC (1.00) | SRCABL1ABL2 | |
| SCHEMBL1657913 | 0.88 | SRC (1.00) | SRCABL1ABL2KDR | |
| SCHEMBL30453979 | 0.88 | SRC (1.00) | SRCABL1ABL2KDR | |
| SCHEMBL1657788 | 0.86 | SRC (1.00) | SRCABL1ABL2FYN | |
| SCHEMBL30453073 | 0.86 | SRC (1.00) | SRCABL1ABL2FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029677-A1 | 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) | WYETH (US) | 2010-02-04 | — | — | US | claimed |
| US-20080318971-A1 | using bosutinib | WYETH (US) | 2008-12-25 | — | — | US | claimed |
| US-7468379-B2 | Inhibition of osteolytic lesions by SRC kinase inhibitors | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-12-23 | — | — | US | claimed |
| US-7417148-B2 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | WYETH (US) | 2008-08-26 | — | — | US | claimed |
| EP-1896020-A1 | INHIBITION OF OSTEOLYTIC LESIONS BY SRC KINASE INHIBITORS | The Board of Regents of The University of Texas System (US) | 2008-03-12 | — | — | EP | claimed |
| US-20070004748-A1 | Inhibition of osteolytic lesions by SRC kinase inhibitors | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2007-01-04 | — | — | US | claimed |
| WO-2006138590-A1 | INHIBITION OF OSTEOLYTIC LESIONS BY SRC KINASE INHIBITORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-12-28 | — | — | WO | claimed |
| EP-1680119-A1 | 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) | Wyeth (US) | 2006-07-19 | — | — | EP | claimed |
| EP-1499594-B1 | PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES | WYETH CORP (US) | 2005-08-17 | — | — | EP | claimed |
| WO-2005047259-A1 | 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) | WYETH (US) | 2005-05-26 | — | — | WO | claimed |
| WO-2005046693-A1 | 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) | WYETH (US) | 2005-05-26 | — | — | WO | claimed |
| US-20050101780-A1 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | WYETH (US) | 2005-05-12 | — | — | US | claimed |
| EP-1499594-A1 | PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES | Wyeth Holdings Corporation (US) | 2005-01-26 | — | — | EP | claimed |
| US-6780996-B2 | KINASE INHIBITORS; ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION | 2004-08-24 | — | — | US | claimed |
| US-20030212276-A1 | Process for the preparation of 7-substituted-3 quinolinecarbonitriles | WYETH HOLDINGS CORPORATION | 2003-11-13 | — | — | US | claimed |
| WO-2003093241-A1 | PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES | WYETH HOLDINGS CORPORATION (US) | 2003-11-13 | — | — | WO | claimed |
| EP-4599890-A2 | SUNITINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2025-08-13 | — | — | EP | disclosed |
| CN-113181362-B | Medicament for preventing and/or treating amyotrophic lateral sclerosis | 国立大学法人京都大学 | 2023-06-13 | — | — | CN | disclosed |
| US-20030212276-A1 | Process for the preparation of 7-substituted-3 quinolinecarbonitriles | WYETH HOLDINGS CORPORATION | 2003-11-13 | — | — | US | disclosed |
| WO-2003093241-A1 | PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES | WYETH HOLDINGS CORPORATION (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212276-A1 | Process for the preparation of 7-substituted-3 quinolinecarbonitriles | MAP4K2, MAP3K7, MAP4K1 | SRC 386/4885ABL1 26/4885ABL2 440/4885 |
| US-20070004748-A1 | Inhibition of osteolytic lesions by SRC kinase inhibitors | SRC, CAMK1, SOST | SRC 1/4885ABL1 1351/4885ABL2 2090/4885 |
| US-20050101780-A1 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | ABL1, MCL1, NPM1 | SRC 244/4885ABL1 1/4885ABL2 8/4885 |
| US-20080318971-A1 | using bosutinib | ABL1, BCR, MCL1 | SRC 345/4885ABL1 1/4885ABL2 11/4885 |
| US-20100029677-A1 | 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) | ABL1, MCL1, NPM1 | SRC 244/4885ABL1 1/4885ABL2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.